LOUISVILLE, Colo., Oct. 6, 2009 – GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association … Continue reading
Tarmogen® Technology Platform Creates Powerful, Targeted Immune Response to Diseased Cells and Drives Family of Oncology-Focused Products LOUISVILLE, Colo. & SUMMIT, N.J. – May 15, 2009 – GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration … Continue reading
Twelve Week Data to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo. – April 23, 2009 – Twelve-week Phase 2 clinical trial data show that patients treated with GI-5005, GlobeImmune’s … Continue reading
LOUISVILLE, Colo., April 16, 2009 – GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in patients with metastatic cancers that over-express carcinoembryonic antigen (CEA). This … Continue reading
Four-Week Data Comparing GI-5005 Plus Standard of Care vs. Standard of Care to be Presented Next Week in Late-Breaking Poster at AASLD Meeting AASLD President Will Highlight Data at President’s Press Conference LOUISVILLE, Colo., Nov. 1, 2008 – Four-week Phase … Continue reading
Data to be Presented Next Week in Late-Breaking Poster at AASLD Annual Meeting LOUISVILLE, Colo., Oct. 28, 2008 – GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company’s therapeutic vaccine candidate … Continue reading
LOUISVILLE, Colo., Sept. 24, 2008 – GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 59th Annual Meeting of the American Association … Continue reading
LOUISVILLE, CO, July 9, 2008 – GlobeImmune, Inc. announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH) to jointly develop products intended to treat … Continue reading
LOUISVILLE, CO – June 24, 2008 – FierceBiotech and GlobeImmune, Inc. announced today that GlobeImmune has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech … Continue reading
LOUISVILLE, CO, May 20, 2008 – GlobeImmune, Inc. announced today completion of the planned enrollment of 120 subjects in a Phase 2 clinical trial to evaluate the GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 … Continue reading